Q-omics provides the consensus-scored MIR101-2 profile across patient tissues and cancer cell-line models. MIR101-2 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, MIR101-2 is differentially expressed in 4, with the highest sampling consensus in BRCA. Additionally, MIR101-2 RNA expression shows 6,682 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KICH, BRCA, and STAD as cancer lineages where MIR101-2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR101-2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR101-2 survival associations across molecular data types. MIR101-2 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR101-2 RNA expression–survival associations across cancer types. High MIR101-2 expression shows unfavorable associations in KICH, READ, CHOL, ACC, DLBC and SARC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for MIR101-2 RNA expression.
This table summarizes MIR101-2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR101-2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR101-2 shows lower tumor expression in BRCA, LUSC and CHOL and higher tumor expression in PRAD. The BRCA box plot shows higher MIR101-2 RNA expression in normal versus tumor tissue (log2 FC = −0.160, t-test p = .013).
This table shows molecular features associated with MIR101-2 in patient tissues and cancer cell lines. In patient samples, MIR101-2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
